Company Overview and News
Chicago, IL – April 18, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include VanEck Vectors Semiconductor ETF (SMH - Free Report) , iShares PHLX Semiconductor ETF (SOXX - Free Report) , PowerShares Dynamic Semiconductor (PSI - Free Report) , SPDR S&P Semiconductor ETF (XSD - Free Report) and First Trust Nasdaq Semiconductor ETF (FTXL - Free Report) .
SOXX AZRE CRK MS.PRE USFD MS.PRF WCG MS.PRG NEP MS.PRA GOLF X MS.PRI MS.PRK AMAT XSD ADM MS TNET
Designed to provide broad exposure to the Technology ETFs category of the U.S. equity market, the SPDR S&P Semiconductor ETF (XSD - Free Report) is a smart beta exchange traded fund launched on 01/31/2006.
WFC WFCNP SOXX WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ SMTC WFC.PRP WFC.PRO MU WFC.PRN IPHI XSD WFC.PRY WFC.PRX WFC.PRW WFC.PRV
The PowerShares Dynamic Semiconductors Portfolio (PSI - Free Report) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Technology ETFs category of the U.S. equity market.
SOXX MU AMAT INTC
The first quarter of 2018 was a bumpy ride for the technology sector, thanks to the slew of bad news, which includes the Russian hacking of computers at the 2018 Olympics, data misuse scandal at Facebook (FB - Free Report) , and the first casualty by a driverless car. This has come as a massive blow to the share prices of tech heavyweights, including Facebook, Apple and Alphabet, dragging the entire sector down.
LRCX SOXX FB SIG MU AMAT NVDA SIG
This has been a brutal March for the tech space with Technology Select Sector SPDR Fund (XLK - Free Report) losing about 5.3% in the last one month (as of Mar 27, 2018). While broad-based factors like Fed policy tightening and trade tensions kept Wall Street downbeat, technology-specific issues like Facebook (FB - Free Report) ’s data breaches, massacre with Nvidia’s self-driving car tests and issues in Twitter bruised big tech names (read: Is the Rout in Tech ETFs Transitory?).
SOXX ARKW FB GOOGL TWTR NFLX NVDA FNG
Chicago, IL – March 28, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cambria Emerging Shareholder Yield ETF (EYLD - Free Report) , Innovator IBD 50 Fund ETF (FFTY - Free Report) , Solar ETF Guggenheim (TAN - Free Report) , iShares PHLX Semiconductor ETF (SOXX - Free Report) and iShares Dow Jones U.
SOXX FCN TUSK TXN IMKTA DAR EYLD CVTI UNFI RCKY VLKAF UFPI AB
Despite the initial surge in US markets on Monday morning, one stock that did not participate in the rally was chip maker Advanced Micro Devices (AMD). The stock quickly turned negative after the open, primarily thanks to a very negative analyst note out of Susquehanna, which calls for nearly 30% downside from Friday's close. Is that logical?
SOXX AMD NVDA
Global superpowers have started mulling over trade tensions starting March. The reason is Trump’s order to levy duties on steel and aluminum imports at the start of the month followed by his announcement to impose up to $60 billion in import duties on Chinese goods by Friday. Previously, Trump levied import tariffs on residential washing machines, as well as solar cells and modules too.
SOXX CARZ SOYB BOE GM.WS.A GM.WS.B GM.WS.C GM GM.WSB BA CUPM ITA CTNN
Reinforcing his protectionist agenda, President Donald Trump sought to levy new tariffs worth up to $60 billion on China, according to Reuters. Mainly Chinese apparel, technology and telecom goods are being subjected to this tariff. This month, Trump has imposed a 25% tariff on steel imports and a 10% on aluminum imports. These tariffs are likely to push up costs and weigh on international sales of U.
SOXX XELB DIA APH CMTL MU BOE AMAT AAPL SRI SSI BA BOOT ITA
The semiconductor space remained largely unaffected by the broad market sell-off seen in early February. This is because the semiconductor industry is clearly leading the broad technology space this year on encouraging fundamentals, solid corporate earnings, strong outlook and investors’ continued appreciation of value-centric traditional stocks. The rally has strengthened courtesy of a series of consolidation, which pushed several chip stocks and ETFs to new highs.
CAVM SOXX MRVL MSCC AVGO NVDA XSD QCOM INTC MCHP FFIN
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to SOXX / iShares PHLX Semiconductor ETF on message board site Silicon Investor.
|Iu0027m a booted Sox (or is it Soxx?) clown...|
as of ET